Biotech Drug Report Generated Aug 17, 2026

vebreltinib

APLM·Apollomics Inc.

BEARISH

Drug Impact Rating3/10

Trial Phase: Phase 2
Time to Market: Unknown / years away — no U.S. IND until 2027 per company guidance; Phase 2 is the furthest stage and there is no filed NDA or PDUFA.
Why 3/10: No hard, dated binary (PDUFA, pivotal readout, or regulatory decision) for vebreltinib is scheduled in the next ~12 months — the company says a U.S. IND is only planned for 2027 and global Phase 2 readout dates are unannounced — so this mid-stage lead asset scores 3, and near-term stock moves will be driven by financing/licensing events rather than a drug catalyst.

Actionable Insight ▼ BEARISH

There is no dated drug catalyst on the calendar for vebreltinib, so APLM is a financing/liquidity story, not a binary trial play: watch for (1) any new equity raise under the effective F-3 shelf (dilution), (2) a re-licensing deal for the regained ex-China rights, and (3) Phase 2 data announcements — the stock's tiny float and wide 52-week range ($3.66–$42.12) mean headline-driven swings can be extreme in both directions.

Price Chart

Loading chart...

Executive Summary

Vebreltinib (APL-101/PLB1001) is Apollomics Inc.'s (Nasdaq: APLM) lead drug, an oral c-MET inhibitor for non-small cell lung cancer, currently in Phase 2 with no U.S. IND yet (planned 2027). The company's finances are the story: $3.3M cash at end-2025, a going-concern warning in its 20-F, a $2M CEO bridge note convertible at an 80% discount, an active F-3 shelf, and a June 2026 license termination after partner LaunXP failed to pay $3.8M (rights to vebreltinib were regained). The stock avoided delisting (Nasdaq MVLS compliance restored July 2026) and trades around $23.40 on a tiny ~2.2M-share float with a 52-week range of $3.66–$42.12.

How It Works

Vebreltinib is an oral pill that blocks the c-MET protein — a cellular switch that, when over-activated by MET gene mutations (MET exon 14 skipping), drives non-small cell lung cancer (NSCLC) cells to grow and spread. Blocking c-MET with a daily pill is a proven strategy: two similar drugs (capmatinib/Tabrecta and tepotinib/Tepmetko) are already FDA-approved for this exact patient population, so vebreltinib is a would-be third entrant targeting a small, genetically defined niche of lung cancer.

Trial Status

Vebreltinib is Apollomics' lead asset in global Phase 2 development. The Chinese Phase 2 study (KUNPENG, NCT04258033, sponsored by license partner Beijing Pearl Biotechnology) in c-MET-dysregulated non-small cell lung cancer is COMPLETED (145 enrolled; primary completion May 2024; study completion June 2025; results not posted on ClinicalTrials.gov in local data). Per its FY2025 report (April 2026), Apollomics is advancing vebreltinib in global Phase 2 trials and planning a U.S. IND submission by 2027. In June 2026 it terminated its ex-China/Macau license to LaunXP for non-payment of a $3.8M balance and regained full ex-China rights to the drug.

The Two-Sided Case

▲ Bull Case5

Validated target with a completed proof-of-concept: the Chinese KUNPENG Phase 2 study (145 patients) in c-MET-dysregulated NSCLC is COMPLETED, de-risking the mechanism for a drug in the same class as two approved products.

Regaining full ex-China/Macau rights to vebreltinib after the LaunXP default (June 2026) gives Apollomics a fresh shot at re-licensing the asset, potentially on better terms, per the company's own 6-K disclosure.

FY2025 discipline: operating expenses cut 64% year-over-year, net loss narrowed to $(10.9)M from $(53.9)M, and $8.5M in licensing revenue was recognized — a materially leaner burn profile.

Nasdaq MVLS delisting risk was resolved (compliance demonstrated June 23–July 7, 2026; status restored to Normal July 9, 2026), removing a near-term listing overhang.

Analyst consensus is constructive (stale, period 2024-12-01): 4 Buy + 2 Strong Buy vs 1 Hold, though no price targets exist in local data.

▼ Bear Case5

Going-concern risk: only $3.3M cash at end-2025, with the 20-F stating funds are insufficient to meet obligations through April 2027 — the company must raise capital to survive, and vebreltinib's development is underfunded.

Dilution overhang: a $2.0M CEO bridge note auto-converts at an 80% discount to the next qualified financing, and the F-3 shelf (effective June 2026) allows further share sales into a ~2.2M-share float.

License partner default: LaunXP failed to pay a $3.8M balance, the ex-China deal was terminated, and Apollomics initiated dispute resolution — the $8.5M revenue booked in 2025 may be at risk and re-licensing is uncertain.

Competition: two c-MET inhibitors (capmatinib/Tabrecta, tepotinib/Tepmetko) are already approved for MET exon 14 NSCLC; vebreltinib has no U.S. IND until 2027 and no registrational trial started, leaving it years behind.

No near-term drug catalyst: no FDA action, no PDUFA, and no dated Phase 3/registrational readout exists in local data; the defining events for the stock are financing and listing mechanics, not drug data.

Upcoming Catalysts

Financing or equity raise under the effective F-3 shelf — likely dilutive given $3.3M cash and the CEO's 80%-discount convertible bridge
Re-licensing of vebreltinib ex-China/Macau rights after the June 2026 LaunXP termination, and any resolution of the $3.8M dispute
Global Phase 2 trial data updates when management schedules them (no dates announced)
Progress toward the planned 2027 U.S. IND submission
Nasdaq MVLS compliance monitoring (recovered July 2026, but at ~$23.40 on ~2.2M shares the buffer is thin)

Source Filing

The SecBot filing or press-release report that triggered this drug report:

Apollomics Inc. 6-K APLM ·Originating report

Sources · 7

Hover a chip for the title

1 sec.gov2 sec.gov3 sec.gov4 sec.gov5 sec.gov6 sec.gov7 globenewswire.com